Cleveland Clinic scientists believe they have identified possible blood biomarkers that could help detect lung cancer, based on the alteration of metabolic processes that happens to patients with the disease at various stages.
A subsidiary of French in vitro diagnostics giant bioMérieux gained Medicare coverage for a new breast cancer test, a vital milestone necessary to compete in today's market.
Sequenta attracted new equity investment from Celgene and other unnamed parties that back the use of its technology in the drug development process and the creation of new ultraprecise diagnostic tests.
Biocept forged a partnership deal with a competitor that aims to build an enhanced molecular diagnostics test for circulating tumor cells in the blood. Success could breed a more precise test that aids patient diagnoses and drug development in equal measure.
Merck Serono is teaming up with London's Institute of Cancer Research and the charitable Wellcome Trust to identify and develop new inhibitors to treat cancer.
In an effort to better understand a certain disease-causing enzyme, British researchers have created a "map" of more than 100 proteins this enzyme is known to affect. They then identified a druglike molecule that blocks this enzyme to preserve these essential proteins.
In late 2014, the push to develop universal companion diagnostics to facilitate personal treatments for multiple cancers appears to be accelerating.
The U.K.'s Inivata raised more than $6.5 million in new financing to help advance its use of circulating tumor DNA to improve cancer testing and treatment.
Conventional drug testing methods for cancer drugs are often unreliable. In vitro studies don't replicate the complex microenvironment surrounding tumors accurately, and oftentimes, animal research doesn't accurately show how therapies might work in people.
A Utah company will rely on a Japanese pharmaceutical partner to help develop and bring to market its diagnostic imaging biomarker for breast and prostate cancer, and potentially other tumors.